Piper Jaffray analyst David Amsellem reiterated his Overweight rating while trimming his price target on Allergen (NYSE: AGN) to $311.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

UBS Cuts Allergan (AGN) PT, Ests But Remains Above ConsensusApril 7, 2016 8:41 AM Anacor Pharma (ANAC) Gains 10% on Takeover SpeculationApril 6, 2016 10:43 AM Allergan (AGN) CEO says Valeant's (VRX) Bausch & Lomb fits profile of business targeted - CNBCApril 6, 2016 9:12 AM Standalone Allergan (AGN) Could Be Worth $300 - RBC April 6, 2016 8:36 AM Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations April 6, 2016 7:13 AM Pfizer, Allergan scrap $160 billion deal after U.S. tax rule changeApril 6, 2016 6:53 AM Allergan (AGN) Affirms Termination of Pfizer (PFE) Merger; Affirms Strength as Standalone CompanyApril 6, 2016 6:47 AM Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)April 6, 2016 6:45 AM Allergan Reiterates Strong Standalone Growth Profile and Strategy Following Termination of Pfizer TransactionApril 6, 2016 6:45 AM Pfizer Announces Termination of Proposed Combination with AllerganApril 6, 2016 6:45 AM Mizuho Securities Downgrades Allergen (AGN) to NeutralApril 6, 2016 6:25 AM